International Journal of Rheumatology
Volume 2019 (2019), Article ID 8635073, 1 page
https://doi.org/10.1155/2019/8635073

Erratum

Erratum to “Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac”

Chris Walker

Pfizer, Walton Oaks, UK

Correspondence should be addressed to Chris Walker; chris.walker@pfizer.com

Received 3 February 2019; Accepted 6 February 2019; Published 2 June 2019

Copyright © 2019 Chris Walker. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac” [1], there was an error in reference where it should be replaced with the article titled “A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis” [2].

References

C. Walker, “Are all oral COX-2 selective inhibitors the same? a consideration of celecoxib, etoricoxib, and diclofenac,” International Journal of Rheumatology, vol. 2018, Article ID 1302835, 12 pages, 2018.

A. K. Matsumoto, A. Melian, D. R. Mandel et al., “A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis,” Journal of Rheumatology, vol. 29, no. 8, pp. 1623–1630, 2002.